drugset / Trial / NCT01131026
Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication
Phase 3
Completed
60 enrolled
Deva Holding A.S.
TC Erciyes University · collabTNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti. · collab
NaSingle-groupOpen-labelTreatment
Summary
Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %. However, the eradication resulting from TRIOL treatment with levofloxacin is expected to be 75 % or higher. If the target results can be reached, it will be concluded that TRIOL treatment with levofloxacin will be an alternative to the triple treatment with clarithromycin as the primary treatment.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Subject | Lansoprazole | Other / unclassified | 30 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |